Slow-growing amelanotic malignant melanoma of the esophagus with long survival: a case report and review of the literature

Hirayama, Yutaka; Tajika, Masahiro; Tanaka, Tsutomu; Ishihara, Makoto; Ohnishi, Sachiyo; Hara, Kazuo; Mizuno, Nobumasa; Hijioka, Susumu; Okuno, Nozomi; T, Abe; Uemura, Naomi; Kawakami, Jiro; Kurahashi, Shintarou; Shimizu, Yasuhiro; Yatabe, Yasushi; Niwa, Yasumasa

doi:10.1055/s-0043-117951

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This patient with amelanotic melanoma responded well to nivolumab treatment and vitiligo occurred shortly after the response, suggesting that his occurrence of vitiligo would be associated with the response. Amelanotic melanoma, a minor subtype of melanoma that accounts for 10–25% of all the melanoma [ 2 ], has little or no melanin pigmentation and does not show typical brown or black color appearance. Generally, amelanotic melanoma exhibits aggressive behavior compared with common cutaneous melanoma and hardly responds to conventional chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

et al. 2021

View full text Add to dashboard Cite

Vitiligo, an acquired depigmenting disorder of the skin that reacts against normal melanocytes, sometimes occurs as an immune-related adverse event in the treatment of melanoma with immune checkpoint inhibitors. It has been known that the occurrence of vitiligo is associated with a favorable therapeutic response in patients with melanoma, but it is not yet clear whether the association also applies to amelanotic melanoma, a minor subtype of melanoma with little or no melanin pigmentation. We report a patient with amelanotic melanoma of the esophagus who responded well to nivolumab treatment. Shortly after the tumor response, vitiligo was found on the patient’s forearms. This case suggests that the occurrence of vitiligo is associated with a favorable response to nivolumab treatment for amelanotic melanoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

et al. 2021

View full text Add to dashboard Cite

show abstract

“… n.a. Surgery and CT Died 8 months after first presentation Hirayama et al [ 14 ] 77/F 2 cm Polypoid tumor Middle esophagus n.a. PMME Surgery No recurence 3 year after surgery Kobayashi et al [ 2 ] 68/M 2 cm Polypoid tumor Middle esophagus T1bN0M0, IA Malignant tumor Surgery No recurrence 1.5 year after surgery Current case 86/F 3 cm Polypoid tumor Distal esophagus T2N0M0, II Squamous cell carcinoma Surgery No recurrent finding 12 months from surgery This article is included in the review of Bisceglia et al [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Primary amelanotic malignant melanoma of the esophagus: a case report

et al. 2019

View full text Add to dashboard Cite

BackgroundPrimary amelanotic malignant melanoma of esophagus, which is a subtype of primary malignant melanoma of the esophagus (PMME), is a very rare disease with a poor prognosis. We herein report a case of the amelanotic type of PMME.Case presentationAn 86-year-old woman was admitted to our hospital with symptoms of dysphagia. An endoscopic examination and constructed radiography revealed an elevated and semipedunculated lesion with an ulcer in the lower thoracic esophagus accompanied by another submucosal lesion of the esophagus. She was diagnosed with esophageal squamous cell carcinoma by a preoperative endoscopic biopsy. We performed thoracoscopy- and laparoscopy-assisted subtotal esophagectomy with lymphadenectomy. Based on the surgical specimens, although there were no melanocytes, we made a diagnosis of a malignant melanoma immunohistochemically; the tumor cells were positive for S-100 protein and HMB45 focally and partially for Melan-A.ConclusionWe experienced a case of primary amelanotic malignant melanoma, and the patient has remained disease-free for 1 year since the surgery. Since the diagnosis of amelanotic type of PMME is difficult, it should be made by the combination of a morphological examination, pathological examination, and immunohistochemistry.

show abstract

“…Amelanotic malignant melanoma of the esophagus is a rare disease, and only 15 such cases have been accumulated from 1996 to 2017 ( 6 – 15 ). Only one cases stated long survival ( 6 ). Other case reports stated a mean survival of approximately 9 months ( 7 – 15 ).…”

Section: Discussionmentioning

confidence: 99%

A report of amelanotic malignant melanoma of the esophagus diagnosed appropriately with novel markers: A case report

et al. 2018

View full text Add to dashboard Cite

The present case study reported of amelanotic malignant melanoma of the esophagus. A 68-year-old man underwent laparoscopic distal gastrectomy for early gastric cancer diagnosis. After gastrectomy, endoscopic examination revealed a protruded lesion lying adjacent to the melanosis area of the esophagus. Histology of the biopsy specimen suggested malignancy, but the diagnosis could not be made. The patient underwent trans-thoraco-abdominal curative subtotal esophagectomy. Immunohistochemical examination of the resected specimen was negative for HBM-45 and Melan-A. However, immunohistochemical examinations of SOX10 (Sry-related HMg-Box gene 10) and KBA.62, which are not associated with melanosome, were strongly positive, and tyrosinase was notably positive. A diagnosis primary of amelanotic malignant melanoma of the esophagus that consisted of only premelanosomes was made. The present findings suggest that, in the diagnosis of malignant melanoma, SOX10 and KBA.62 may be useful, particularly in diagnosing amelanotic malignant melanoma.

show abstract

Slow-growing amelanotic malignant melanoma of the esophagus with long survival: a case report and review of the literature

Cited by 3 publications

References 7 publications

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

Primary amelanotic malignant melanoma of the esophagus: a case report

A report of amelanotic malignant melanoma of the esophagus diagnosed appropriately with novel markers: A case report

Contact Info

Product

Resources

About